英国原发性胆汁性胆管炎患者瘙痒常见且治疗不足
研究分析英国原发性胆汁性胆管炎(PBC)队列中2194例患者,发现73.5%曾出现瘙痒,34.5%为持续性瘙痒、11.7%为严重瘙痒,仅37.4%持续性瘙痒和50%严重瘙痒患者曾用考来烯胺。年轻诊断年龄和较高碱性磷酸酶与持续性瘙痒相关。
要点
- 73.5%的PBC患者曾出现瘙痒,34.5%为持续性瘙痒,11.7%为严重瘙痒。
- 持续性瘙痒者仅37.4%、严重瘙痒者仅50%曾接受考来烯胺治疗。
- 诊断时年龄较轻和诊断后12个月碱性磷酸酶较高与持续性瘙痒相关。
核心结论
- 在英国大型全国性PBC队列中,瘙痒患病率高且指南推荐的治疗不足。
- 患者自报数据用于确定瘙痒患病率和治疗是可靠的。
- 诊断时年龄较轻和较高碱性磷酸酶水平与持续性瘙痒相关。
- 需要提高英国PBC瘙痒的认知和管理。
研究设计与样本
- 横断面和纵向研究,纳入英国所有临床中心招募的UK-PBC队列患者。
- 2194例患者在2011年初次评估时完成纸质问卷,并于2014年和2017年再次调查。
- 自报治疗数据与临床实践研究数据链(CPRD)初级保健数据库中PBC队列的处方记录进行验证。
主要发现
- 初次评估时1613例(73.5%)患者自PBC发病以来曾出现瘙痒,34.5%报告持续性瘙痒,11.7%报告严重瘙痒。
- 持续性瘙痒患者中仅37.4%、严重瘙痒患者中仅50%报告曾接受考来烯胺治疗。
- 持续性瘙痒患者中利福平使用频率为11%,严重瘙痒患者中为23%。
- 2011年和2014年调查(共1423例患者)显示自报瘙痒数据一致。
- UK-PBC队列中接受考来烯胺或纳曲酮治疗的比例(37.4%和4.4%)与CPRD队列(30.4%和4.4%)无显著差异(考来烯胺P=0.07,纳曲酮P=0.32)。
关键数值与推荐
- 持续性瘙痒定义为疾病过程中频繁或持续存在的瘙痒。
- 严重瘙痒定义为疾病过程中PBC-40瘙痒领域评分≥12。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Little is known about the prevalence or treatment of pruritus associated with primary biliary cholangitis (PBC). We analyzed data from patients with PBC recruited from all clinical centers in the United Kingdom (UK) to characterize the prevalence, severity, progression, and treatment of pruritus. METHODS: We performed cross-sectional and longitudinal studies of patients in the UK-PBC cohort to assess trajectories of pruritus. Data on pruritus frequency, severity, and therapy were collected via paper questionnaires completed by 2194 patients at their initial assessment in 2011 and then again in 2014 and 2017. Self-reported treatment data were validated against the prescription record of PBC cohort in the Clinical Practice Research Datalink, a primary care database. We defined persistent pruritus as itch that occurs frequently or all the time and severe pruritus as PBC-40 pruritus domain scores of 12 or more, throughout their disease course. Latent class mixed models were used to study pruritus trajectories and identify factors associated with high pruritus. RESULTS: At initial assessment, 1613 (73.5%) patients had experienced pruritus at some point since their development of PBC-persistent pruritus was reported by 34.5% of the patients and severe pruritus by 11.7%. Only 37.4% of patients with persistent pruritus and 50% with severe pruritus reported ever receiving cholestyramine. Frequencies of rifampicin use were 11% in patients with persistent pruritus and 23% in patients with severe pruritus. Comparison of 2011 and 2014 surveys (comprising 1423 patients) showed consistent self-reported data on pruritus. Proportions of patients in the UK-PBC cohort treated with cholestyramine or naltrexone (37.4% and 4.4%) did not differ significantly from proportions treated in the Clinical Practice Research Datalink cohort (30.4% and 4.4%) (P = .07 for cholestyramine and P = .32 for naltrexone). Latent class mixed models (n = 1753) identified 3 different groups of pruritus. Multivariable analysis identified younger age at diagnosis and higher level of alkaline phosphatase at 12 months after diagnosis as factors significantly associated with persistent high pruritus. CONCLUSIONS: In a large national cohort study of patients with PBC, we found a high prevalence of pruritus and inadequate guideline-recommended therapy. Patient-reported data used to determine pruritus prevalence and treatment are reliable. Younger age and levels of higher alkaline phosphatase were associated with persistent pruritus. We need to increase awareness and management of pruritus in PBC in the UK.
引用
- Hegade VS, Mells GF, Fisher H, et al. Pruritus Is Common and Undertreated in Patients With Primary Biliary Cholangitis in the United Kingdom. Clin Gastroenterol Hepatol. 2018. PMID: 30557739. doi:10.1016/j.cgh.2018.12.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。